How many biosimilars are approved in the EU 2020?
58 biosimilars
In the EU today, 58 biosimilars are approved for 16 reference products (GaBI, 2020a) (see Figure 1).
Are biosimilars interchangeable in Europe?
Many of the best-selling ‘blockbuster’ biological medicinal products are, or will soon be, facing competition from similar biological medicinal products (biosimilars) in the EU. Our conclusion is that biosimilars licensed in the EU are interchangeable.
Is Filgrastim a biosimilar?
Filgrastim-sndz is the first biosimilar drug approved by the FDA for use in the United States. A series of studies, including a large clinical trial, demonstrated that the efficacy and safety of filgrastim-sndz is comparable to the reference drug, filgrastim, in preventing neutropenia in patients with cancer.
How many biosimilars are approved in Europe?
Biosimilars/General Posted 08/07/2011 Omnitrope (somatropin) was the first product approved in the EU as a biosimilar in 2006 [2].
When was the first biosimilar Europe?
2006
The EU has pioneered the regulation of biosimilar medicines by establishing a solid framework for their approval and by shaping biosimilar development globally. Since the EU approved the first biosimilar in 2006, healthcare professionals have gained increasing experience with their use.
Why are the EU and US biosimilar markets so different?
The differences between the US and EU biosimilar markets This is due to a difference in the patent landscape, with some EU patents ending earlier and some originator companies generating more patent barriers in the US.
When was the first biosimilar approved?
On March 6, 2015, the FDA approved filgrastim-sndz (Zarxio; Sandoz/Novartis), the first biosimilar ever to receive approval in the United States.
How many biosimilars are approved by FDA?
thirty
Official Answer. The number of biosimilars currently approved by the FDA is thirty-one. The most recent biosimilar approval was Byooviz (ranibizumab-nuna) on September 17, 2021.
When did biosimilars start?
US approved biosimilars
| Date of Biosimilar FDA Approval | Biosimilar Product | Original Product |
|---|---|---|
| September 23, 2016 | adalimumab-atto/Amjevita | adalimumab/Humira |
| April 21, 2017 | infliximab-abda/Renflexis | infliximab/Remicade |
| August 25, 2017 | adalimumab-adbm/Cyltezo | adalimumab/Humira |
| September 14, 2017 | bevacizumab-awwb/Mvasi | bevacizumab/Avastin |
How the US compares to Europe on biosimilar approvals and products in the pipeline?
To date, the U.S. has considerably lagged behind Europe’s expansion of biosimilar drug options. Sandoz’s filgrastim biosimilar, Zarxio®, received the first U.S. approval in 2015, whereas nine filgrastim biosimilars have been approved in Europe dating back to multiple authorizations in 2008.
What is the difference between sandsandoz’s Zarxio® and other filgrastim biosimilars?
Sandoz’s filgrastim biosimilar, Zarxio®, received the first U.S. approval in 2015, whereas nine filgrastim biosimilars have been approved in Europe dating back to multiple authorizations in 2008. Zarxio® (in the U.S.) and Zarzio® (in Europe) are biosimilar to the reference product Neupogen® marketed by Amgen and originally licensed in 1991.
Is the EU’s Head Start on biosimilars leading to more biosimilar approvals?
As illustrated in the following graph, while the EU’s significant head start led to an imbalance in the number of biosimilar drugs available in the respective markets, the EU’s relatively higher rate of approvals in recent years has widened its lead over the United States.
How many Omnitrope biosimilar applications have been approved in Europe?
Since Sandoz’s somatotropin biosimilar Omnitrope® was first authorized on April 12, 2006, an additional 59 applications have been approved in Europe. Six of the authorizations have been withdrawn post-approval ( Table 1 ).
How big is the global market for biosimilar drugs?
As pharmaceutical drug costs attract increasing media attention and political scrutiny, a growing number of biosimilar drugs are set to enter the U.S. and European markets in the coming years. Global sales for the top ten branded biologic drugs totaled approximately $71 billion in 2017 [1] .